Mass production method of antimicrobial peptide and DNA construct and expression system thereof

ABSTRACT

The present invention relates to DNA constructs that can produce antimicrobial materials efficiently from microorganisms and the preparation method thereof. The present invention also relates to the useful vector for the DNA construct. The DNA construct according to the present invention comprises a first gene coding for entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide. According to the present invention, antimicrobial peptides can be mass-produced by the following steps: preparing an expression vector containing a DNA construct comprising a first gene coding for an entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide; transforming the bacterial host cells with the above-mentioned vector, culturing the transformed cell to express the above-mentioned DNA construct; and recovering the above antimicrobial peptide.

TECHNICAL FIELD AND BACKGROUND ART

The present invention relates to the recombinant DNA technology. The present invention also relates to the mass-production of antimicrobial materials from microorganisms and a DNA construct and vector system. Biologically active peptide (antimicrobial peptide hereinafter) has little chance to develop resistance since the antimicrobial peptides show activity by a mechanism that is totally different from that of conventional antibiotics which have a serious problem of developing resistance. Therefore, the antimicrobial peptides have a high industrial applicability in the fields of pharmaceutics and the food industry.

The main obstacle in the industrial use of the antimicrobial peptide, however, is the difficulty in economical mass-production of the antimicrobial peptides. For instance, the production of the antimicrobial peptides by chemical synthesis is not economical. Also, there have been attempts to produce antimicrobial peptides by genetic engineering using microorganisms, in this case, however, the expression levels of the antimicrobial peptides are very low.

U.S. Pat. No. 5,206,154 provides a DNA construct which comprises a polypeptide gene which is capable of suppressing the bactericidal effect of cecropin, and a cecropin gene fused to the polypeptide gene. An example of such polypeptide disclosed in the patent is the araB gene.

U.S. Pat. No. 5,593,866 provides a method for a microbial production of a cationic antimicrobial peptide, wherein the cationic peptides is expressed as a fusion to an anionic peptide to avoid degradation by a bacterial protease.

DISCLOSURE OF THE INVENTION

The present invention provides a DNA construct to mass-produce a antimicrobial peptides. The present invention also provides a DNA construct that can produce and recover antimicrobial peptides effectively from microorganisms.

Also, the present invention provides gene multimers that can increase the efficiency of expression, separation and purification of desired peptides and the construction method of such construct.

Further, the present invention provides an expression vector to mass-produce antimicrobial peptides from microorganisms.

Further, the present invention provides a method to mass-produce antimicrobial peptides form microorganisms.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A, 1B, 1C, 1D, 1E and 1F, herein referred to collectively as FIG. 1, are a nucleotide sequence coding for an antimicrobial peptide of the present invention.

FIGS. 2A, 2B, 2C and 2D, herein referred to collectively as FIG. 2, are a nucleotide sequence coding for a fusion partner.

FIGS. 3A and 3B, herein referred to collectively as FIG. 3, are a scheme of a fusion method between the fusion partner and the MSI-344 gene by generating a sequence encoding producing CNBr cleavage site.

FIGS. 4A and 4B, herein referred to collectively as FIG. 4, are a scheme of a fusion method between the fusion partner and the MSI-344 gene by generating a sequence encoding producing hydroxylamine cleavage site.

FIG. 5 is a scheme of the construction of the transcriptionally fused multimer.

FIGS. 6A and 6B, herein referred to collectively as FIG. 6, are a scheme of the construction of the pGNX2 vector.

FIG. 7 is a scheme of the construction of the pT7K2.1 vector.

FIG. 8 is a scheme of the construction of the pGNX3 vector.

FIG. 9 is the pGNX4 vector.

FIG. 10 is a scheme of the construction of the pGNX5 vector.

FIG. 11 is a SDS-PAGE electrophoretic analysis of the lysates of the transformants expressing MSI-344 by an induction with lactose or IPTG.

FIG. 12 is a SDS-PAGE electrophoretic analysis of MSI-344 expression with various vectors.

FIG. 13a is a SDS-PAGE electrophoretic analysis of the lysates of the transformants expressing various antimicrobial peptides by induction with lactose.

FIG. 13b is a SDS-PAGE electrophoretic analysis of the lysates of the transformants expressing various antimicrobial peptides by an induction with lactose.

FIGS. 14a, 14 b, 14 c and 14 d are SDS-PAGE electrophoretic analyses of the lysates of the transformants expressing various antimicrobial peptides by an induction with lactose.

FIG. 15 is a SDS-PAGE electrophoretic analysis of the lysates of the transformants expressing the monomer, dimer and tetramer of the fusion genes.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a DNA construct for mass-producing antimicrobial peptides effectively in E. coli or other prokaryotes.

One of the essential conditions for mass production of the antimicrobial peptides from microorganisms is to efficiently neutralize the toxicity of the antimicrobial peptides against the microorganisms. To this end, the present invention provides a DNA construct in which a whole gene, partial or derivatives of the purF gene (glutamine pyrophosphoribosyl pyrophosphate amidotransferase; Genbank No.: X12423) (Tso et al., J. Biol. Chem., 257: 3525, 1982, Makaroff et al., J. Bio. Chem., 258: 10586, 1983) is fused as a fusion partner to the gene coding for antimicrobial peptides.

The derivatives of purF gene used as a fusion partner in the DNA construct according to the present invention allows mass-production of the antimicrobial peptides as a fused polypeptide with purF derivatives in Escherichia coli without killing the host cells. Therefore, it is possible to mass-produce the desired antimicrobial peptides from the host microorganisms using a strong expression system since they are not lethal to the host cell. In the case of using a fusion partner according to the present invention to express peptides, it is possible to cleave and separate the antimicrobial peptides from the fusion protein by using a protease or other chemicals. To achieve this, for instance it is possible to insert a DNA sequence between the fusion partner and antimicrobial peptide genes encoding the cleavage site for proteases such as Factor Xa or enterokinase or chemicals such as CNBr or hydroxylamine.

For instance, to provide a CNBr cleavage site, restriction enzyme site containing Met codon (ATG) with correct leading frame such as Afl III, Bsm I, BspH I, BspLU11 I, Nco I, Nde I, Nsi I, Ppu10 I, Sph I, Sty I, or their isoschizomers could be inserted into the 3′ end of the fusion partner. It is possible to make in-frame fusion of the fusion partner and the gene coding for antimicrobial peptide by inserting the restriction enzyme site into the 5 end of the gene coding for antimicrobial peptide that produces a compatible end to the enzyme site of the fusion partner.

It is also possible to insert a DNA sequence coding for Asn-Gly between the fusion partner and antimicrobial peptide genes. For instance, two genes can be fused by the following method. After inserting a restriction enzyme or isoschizomer site containing an Asn codon with correct reading frame at the 3′ end of the fusion partner, the fusion partner is cleaved by the enzyme. At the 5′ end of the gene coding for antimicrobial peptide, a restriction enzyme site containing a Gly codon with correct reading frame that produces a compatible or blunt end with the corresponding site of the fusion partner is inserted and cleaved with the corresponding enzyme. The two cleaved DNA fragments may be connected to produce the fused gene. The genetic construct according to the present invention may be inserted into the host cell by cloning into any kind of expression vector, that is conventionally used in this field such as plasmid, virus or other vehicles that can be used to insert or incorporate the structural genes.

The present invention relates to a multimer that can increase the expression level by increasing the copy number of the gene of the required product and which can be separated and purified conveniently and the preparation method thereof.

The multimer according to the present invention is constructed by the following units.

1) A first restriction enzyme site that can generate an initiation codon Met, 2) a structural gene, 3) a ribosome binding site (RBS), and 4) a second restriction enzyme site generating a cohesive end which can be in-frame fused to the cohesive end generated by the first restriction enzyme and which can generate the initiation codon. Here, the stop codon and the RBS of the structural gene may overlap by ca. 2 bp or may be separated as far as 500 bp. The distance between the RBS and the second restriction enzyme site that can generate the initiation codon may be ca. 5 to 30 bp. The 3′ and 5′ ends of the multimer may be cleaved by the first or second restriction enzyme, respectively.

The multimer according to the present invention may be prepared by a variety of techniques known in the field of genetic engineering. One of the examples of such preparation method is given below.

After cleaving the units of a gene given above by the first and second restriction enzymes, the cleaved units is connected to produce a mixture containing multimers that include each unit with the same direction and multimers that have more than one unit with reverse direction. Since the multimers that contain more than one unit with reverse direction will have the first or second restriction enzyme site regenerated at the connection site, the multimer mixture may be cleaved simultaneously by the first and second restriction enzymes and separated by agarose gel electrophoresis, for instance, to separate the multimers those have units with the same direction only. The multimer according to the present invention is a transcriptionally fused multimer. This means that the repeated genes are transcribed into a single mRNA, but the gene expression product is not connected. In other words, the multimer is translated into many copies of a single product, In the case of the conventional translationally fused multimer, the desired product is present as a concatemer in a single polynucleotide, and an additional cleavage process is necessary to obtain the desired active product in case that the expression product is a fusion protein, it requires a greater amount of reagent to cleave only with lower efficiency when compared to the transcriptionally fused multimer. Compared to the translationally fused multimer, the expressed multimer of the present invention does not require additional cleavage processes or in the case it requires cleavage processes such as fused proteins, the amount of the reagent for the cleavage may be reduced since the number of peptide bonds to be cleaved per mole of the fused peptide is relatively smaller than the translationally fused multimer.

The multimer of the present invention may increase the gene expression in the host cell, have advantages in cleaving and purifying the desired product, and express in the host more efficiently when compared to the monomer. The multimer and the preparation method thereof are not limited in preparing peptides or fusion peptides. It can be widely applicable in expressing the unfused or fused gene coding for enzymes, hormones and antimicrobial polypeptides in microorganism.

Therefore, it is desirable to produce the DNA construct of the present invention in the form of transcriptionally fused multimer. In the case of preparing the DNA construct of the present invention in the form of transcriptionally fused multimer, it is advantageous to cleave and purify the products, and the multimer may be expressed in the host more efficiently than the monomer.

The present invention also relates to the expression vector that may induce the expression of foreign genes by lactose which is more economical than IPTG.

The expression vector according to the present invention is composed of high copy number replication origin, strong promoter and structural gene, and does not include lacl^(q) gene.

The replication origin may be colE1 or p15A in the present invention. Examples of the strong promoters include tac, trc, trp, T7Φ10, P_(L), other inducible or constitutive promoters in the microorganisms. Additionally, a selection marker gene that may be used to select the transformants of the vector may be included. These marker genes include antibiotic resistant genes against antibiotics such as ampicillin, kanamycin, tetracyline and chloramphenicol, or the genes that complement the auxotrophy of the host. Gene expression using the expression vector according to the present invention can be induced efficiently by adding lactose instead of IPTG preferably by adding IPTG and lactose simultaneously.

As an example, after transforming the plasmid containing the structural gene into the host cells, transformants are primary-cultured for 5 to 18 hours at 30-37° C. in a culture medium that include 50-300 μg/ml kanamycin. Afterwards, they are diluted to 1% (v/v) in a fresh media and cultured at 30-37° C. To induce the expression, 0.01 mM-10 mM IPTG is added when the OD₆₀₀ reaches 0.2-2 in case of IPTG induction, or 0.2-2% lactose is added when the OD₆₀₀ reaches 0.2-2, or at the time of inoculation in the case of lactose induction. IPTG and lactose can be used simultaneously with a significantly reduced amount of IPTG. Additionally, it is desirable to include a transcriptional terminator in the expression vector according to the present invention.

It is possible to obtain the expression product as an inclusion bodies using the expression vector of the present invention. This property is useful in producing a product lethal to the host.

A vector containing a structural gene of the present invention may be transformed into microorganisms by using conventional methods used in the fields of the present invention. For instance, the transformation may be achieved by CaCl₂ method or by physical methods such as electrophoration or microinjection into prokaryotic cells such as E. coli. There is no specific limitation for the host. For instance E. coli strain may be selected form BL21(DE3), BLR(DE3), B834(DE3), AD494(DE3), JM109(DE3), HMS174(DE3), UT400(DE3) and UT5600(DE3). Culture medium could be selected from LB, M9, M9CA, and R according to the characteristics of the host or transformants cells. Growth factors may be added to the media depending on the host requirements.

LB medium (bacto-tryptone 10 g/l, yeast extract 5 g/l, NaCl 10 g/l)

M9 medium (Na₂PO₄ 7H₂O 12.8 g/l, KH₂PO₄ 3.0 g/l, NaCl 0.5 g/l, NH₄Cl 1 g/l, glucose 4 g/l, MgSO₄ 2 mM, CaCl₂ 0.1 mM)

M9CA medium (M9 medium+0.2% casamino acid)

R medium (Reisenberg medium; KH₂PO4 13.3 g/l, (NH₄)₂PO₄ 4.0 g/l, citric acid 0.17 g/l, MgSO₄ 7H₂O 0.22 g/l, glucose 20 g/l, trace element solution 10 ml/l)

Trace element solution (ferric citrate 7.3 g/l, CoCl₂ 6H₂O 0.5 g/l, MnCl₂ 4H₂O 3.2 g/l, CuCl₂ 2H₂O 0.3 g/l, H₃BO₃ 0.7 g/l, NaMoO₄ 2H₂O 1.68 g/l, Thiamin HCl 0.5 g/l, EDTA 1 g/l)

The invention will be further illustrated in detail by the following examples. It will be apparent to those having conventional knowledge in this field that these examples are given only to explain the present invention more clearly, but the invention is not limited to the examples given below.

EXAMPLE 1 Preparation of a Gene Coding for an Antimicrobial Peptide

Two different MSI-344 genes were synthesized by the PCR method to express MSI-344 gene efficiently in E. coli and to ease the gene manipulation (FIG. 1). Template for PCR was pNH18a-MBP-MSI-78 described in Korean patent application 97-29426. Sequence (a) (SEQ ID NO. 55) was synthesized using primers No. 1 (SEQ ID NO. 1) and No. 2 (SEQ ID NO. 2) in Table 1 which was designed to separate MSI-344 by CNBr cleavage from the fusion peptide, and Sequence (b) (SEQ ID NO. 57) was synthesized using primers No. 3 (SEQ ID NO. 3) and No. 4 (SEQ ID NO. 4) in Table 1 which was designed to be cleaved by hydroxylamine. To subclone MSI-344 gene with correct reading frame into the expression vector, Nde1 (Sequence (a)) and SmaI (Sequence (b)) sites were inserted in front of MSI-344 gene and stop codons TAA and TGA were inserted behind the MSI-344 gene. Also to construct the transcriptional multimer, a ribosome binding site that overlaps 1 base pair with the stop codon and Ase I site were inserted. These two MSI-344 genes were cloned into pCR2.1 vector (Invitrogen, USA) to prepare vector pCRMSI containing sequence (a) and vector pCRMSI' containing sequence (b).

The antimicrobial peptide genes in FIG. 1 were prepared by annealing chemically synthesized oligonucleotides (Table 1) or by performing PCR after annealing. In the case of Apidaecin I (SEQ ID NO. 41), Indolicidin (SEQ ID NO. 51), and Tachyplesin I (SEQ ID NO. 61), DNA sequence was based on the amino acid sequence of a peptide (Maloy and Kark, Peptide Science, 37: 105, 1995) and the gene was chemically synthesized by using codons that can maximize the expression level in E. coli. In the case of Bombinin (SEQ ID NO. 43), CPF1 (SEQ ID NO. 45), Drosocin (SEQ ID NO. 47), Melittin (SEQ ID NO. 53), HNP-I (SEQ ID NO. 49), PGQ (SEQ ID NO. 59), and XPF (SEQ ID NO. 63), the N- and C-terminal oligonucleotides which were designed to anneal to each other by 8-10 bp overlaps, were synthesized and the peptide gene was synthesized by PCR after annealing two oligonucleotides. The characteristics of each antimicrobial peptide are listed in Table 2.

Sequences (5′ ---> 3′) Primers  1 TCCGGATCCATATGGGTATCGGCAAAT Primers for the syn- TCCTG (SEQ ID NO. 1) thesis of MSI-344 (32 mer)  2 GCATTAATATATCTCCTTCATTACTTTT Primers for the syn- TCAGGATTTTAACG (SEQ ID NO. 2) thesis of MSI-344 (42 mer)  3 GGATCCCGGGATCGGCAAATTCCTGA Primers for the syn- AAAAGG (SEQ ID NO. 3) thesis of MSI-344 (32 mer)  4 GGATCCATTAATATATCTCCTT Primers for the syn- CATTAC thesis of MSI-344 (SEQ ID NO. 4) (28 mer)  5 GGTAACAACCGTCCGGTTTACATCCCG Primers for the syn- CAGCCGCGTCCGCCGCACCCGCGTAC thesis of Apidaecin I TTGA (SEQ ID NO. 5) (57 mer)  6 AATTCTCAAGTACGCGGGTGCGGCGG Primers for the syn- ACGCGGCTGCGGGATGTAAACCGGAC thesis of Apidaecin I GGTTGTTACC (SEQ ID NO. 6) (62 mer)  7 GGTATCGGTGCGCTGTCTGCGAAAGG Primers for the syn- TGCGCTGAAAGGTCTGGCGAAA thesis of Bombinin (SEQ ID NO. 7) (48 mer)  8 CGAATTCTCAGTTCGCGAAGTGTTGCG Primers for the syn- CCAGACCTTTCGCCAGACCTTTCAGCG thesis of Bombinin CACC (SEQ ID NO. 8) (58 mer)  9 GGTTTCGCGTCTTTCCTGGGTAAAGCG Primers for the syn- CTGAAAGCGGCGCTGAAAATC thesis of CPF (SEQ ID NO 9) (48 mer) 10 CGAATTCTCACTGCTGCGGCGCACCAC Primers for the syn- CCAGCGCGTTCGCACCGATTTTCAGC thesis of CPF GCCGCTT (SEQ ID NO. 10) (60 mer) 11 GGTAAACCGCGTCCGTACTCTCCGCG Primers for the syn- TCCGACCTCTCAC (SEQ ID NO. 11) thesis of Drosocin (39 mer) 12 CGAATTCTCAAACCGCGATCGGACGC Primers for the syn- GGGTGAGAGGTCGGACGCGGAGA thesis of Drosocin (SEQ ID NO. 12) (49 mer) 13 GCATGCCATGGCGTGCTACTGCCGTAT Primers for the syn- CCCGGCGTGCATCGCGGGTGAACGTC thesis of HNP-1 GTTACGG (SEQ ID NO. 13) (60 mer) 14 CGAATTCTCAGCAGCAGAACGCCCAC Primers for the syn- AGACGACCCTGGTAGATGCAGGTA thesis of HNP-1 CCGTAACGAC (SEQ ID NO. 14) (60 mer) 15 CATGATCCTGCCGTGGAAATGGCCGT Primers for the syn- GGTGGCCGTGGCGTCGTTGAG (SEQ ID thesis of Indolicidin NO. 15) (47 mer) 16 AATTCTCAACGACGCCACGGCCACC Primers for the syn- ACGGCCATTTCCACGGCAGGAT thesis of Indolicidin (SEQ ID NO. 16) (47 mer) 17 GGTATCGGTGCGGGTATCGGTGCGGT Primers for the syn- TCTGAAAGTTCTGACCACCGGTCTGCC thesis of Melittin GGCGCTG (SEQ ID NO. 17) (48 mer) 18 CGAATTCTCACTGCTGACGTTTACGTT Primers for the syn- TGATCCAAGAGATCAGCGCCGGCAGA thesis of Melittin CCGGT (SEQ ID NO. 18) (58 mer) 19 GGTGTTCTGTCTAACGTTATCGGTTAC Primers for the syn- CTGAAAAAACTGGGTACC thesis of PGQ (SEQ ID NO. 19) (45 mer) 20 CGAATTCTCACTGTTTCAGAACCGCGT Primers for the syn- TCAGCGCACCGGTACCCAGTTTTTT thesis of PGQ CAG (SEQ ID NO. 20) (55 mer) 21 CATGAAATGGTGCTTCCGTGTTTGCTA Primers for the syn- CCGTGGTATCTGCTACCGTCGTTGCCG thesis of Tachyplasin TTGAG (SEQ ID NO. 21) (59 mer) 22 AATTCTCAACGGCAACGACGGTAGC Primers for the syn- AGATACCCCGGTAGCAAACACGGAAG thesis of Tachyplasin CACCATTT (SEQ ID NO. 22) (59 mer) 23 GGTTGGGCGTCTAAAATCGGTCAGAC Primers for the syn- CCTGGGTAAAATCGCGAAAGTT thesis of XPF (SEQ ID NO. 23) (48 mer) 24 CGAATTCTCATTTCGGCTGGATCAGTT Primers for the syn- CTTTCAGACCAACTTTCGCGATTTTA thesis of XPF CCCAG (SEQ ID NO. 24) (58 mer) 25 GGATCCATATGTGCGGTATTGTCGGTA Primers for the syn- TCG (SEQ ID NO. 25) thesis of F (30 mer) 26 CATATGGCGAGCTTCAAATACATCG Primers for the syn- (SEQ ID NO. 26) thesis of F (25 mer) 27 GGATCCATATGTGCGGTATTGTCGGTA Primers for the syn- TCG (SEQ ID NO. 27) thesis of F′ (30 mer) 28 GGATCCAATATTAGCTTCAAATACATC Primers for the syn- GCTC (SEQ ID NO. 28) thesis of F′ (31 mer) 29 GGATCCATATGTGCGGTATTGTCGGTA Primers for the syn- TCG (SEQ ID NO. 29) thesis of F3 (30 mer) 30 GGATCCAATATTCGCATGCGCAGCTTC Primers for the syn- AAATACATCG (SEQ ID NO. 30) thesis of F3 (HA) (37 mer) 31 CGGGATCCACATGTGGCGAGCTTCAA Primers for the syn- ATAC (SEQ ID NO. 31) thesis of F3 (CB) (30 mer) 32 GGATCCATATGTGCGGTATTGTCGGTA Primers for the syn- TCG (SEQ ID NO. 32) thesis of F4 (30 mer) 33 GCGGATCCACATGTCGGCTTCCAG Primers for the syn- (SEQ ID NO. 33) thesis of F4 (CB) (24 mer) 34 AATATTGTCGGCTTCCAGCGGGTAG Primers for the syn- (SEQ ID NO. 34) thesis of F3 (HA) (25 mer) 35 CATATGCTTGCTGAAATCAAAGG Primers for the syn- (SEQ ID NO. 35) thesis of BF (23 mer) 36 AATATTGCCAGCACCCTCCTGTCCTCG Primers for the syn- GTG thesis of BF (SEQ ID NO. 36) (30 mer) 37 TTCGCTTGCGCGACCACT (SEQ ID NO. Primers for purF 37) G49A mutant (18 mer) 38 TGCGAACGGGTGGAGCCGTTAGACTG Primers for purF (SEQ ID NO. 38) N102L mutant (26 mer) 39 GCGGATCCAAGAGACAGGATGAGGAT Primers for the syn- CGTTTCGC (SEQ ID NO. 39) thesis of kan^(R)gene (34 mer) 40 CGGATATCAAGCTTGGAAATGTTGAA Primers for the syn- TACTCATACTCTTC thesis of kan^(R)gene (SEQ ID NO. 40) (40 mer)

TABLE 2 Amino acid Molecular residue weight (kDa) Origin Apidaecin I 18 2.11 Insect (A. mellifera) Bombinin 24 2.29 Frog (B. variegata) Cecropin A 36 3.89 Moth (H. cecropia) CPF1 27 2.60 Frog (X. Laevis) Drosocin 19 2.11 Fly (D. melanogaster) HNP1 30 3.45 Human (alpha-defensin) Indolicidin 13 1.91 Cow MSI-344 22 2.48 Frog (X. laevis) Melittin 26 2.85 Insect (H. cecropia) PGQ 24 2.33 Frog (X. laevis) Tachyplesin I 17 2.27 Crab (T. tridentatus) XPF 25 2.64 Frog (X. laevis)

EXAMPLE 2 Preparation of Fusion Partner

To use as a fusion partner, purF derivatives shown in FIG. 2 were obtained from the chromosomes of E. coli and Bacillus subtilis using PCR. The fusion partner F was prepared by CNBr cleavage, and F′, F5 and BF by for hydroxylamine cleavage. F3 and F4 were prepared as two different forms; one for CNBr cleavage (F3(CB), F4(CB)), and another for hydroxylamine cleavage (F3(HA), F4(HA), F4a(HA)). Fusion partners F, F′, F3(HA), F3(CB), F4(HA), F4a(HA), F4a(CB), F5, BF are indicated in sequences No. 1-9, respectively.

1) purF derivative F (SEQ ID NO. 73)

The derivative is a coding for 61 amino acid from the N-terminus of the E. coli purF protein (FIG. 2). Nde I site including start codon Met was inserted at the 5′ end, and Nde I site including Met codon that encodes cleavage site for CNBr was inserted at the 3′ end.

2) purF derivative F′ (SEQ ID NO. 75)

To remove the internal hydroxylamine cleavage site, the 49^(th) glycine residue (GGG) was substituted with alanine (GCG, see FIG. 2) by site-directed mutagenesis using primer #36 in Table 1, and Ssp I site containing AAT coding for asparagine was added after alanine codon (number 57) by PCR to form a hydroxylamine cleavage site.

3) purF derivative F3

The 49^(th) glycine residue was substituted with alanine as in F′. Asparagine at the 58th residue was substituted with alanine and alanine-asparagine was added after the 59th histidine (F3(HA)) (SEQ ID NO. 77). In case of F3 for CNBr cleavage (F3(CB)) (SEQ ID NO. 79), a DNA sequence that codes for Met and includes BspLU11I site was added after histidine at the 59th residue.

4) PurF derivative F4

This derivative is composed of 159 amino acid residues from the N-terminus of the purF protein. There exists two hydroxylamine sites in wild-type purF protein. To remove these sites, the 102nd asparagine codon (AAC) was substituted with leucine codon (CTC, underlined in Table 2) by site-directed mutagenesis with primer #37 (Table 1) to form F4(HA) (SEQ ID NO. 81). F4a(HA) (SEQ ID NO. 83) was prepared by double substitution of the 49th glycine with alanine and the 102^(nd) asparagine with leucine. In the case of F4(HA) and F4a(HA) for hydroxylamine cleavage, the SspI site including asparagine codon was added at the 3′ end. In the case of F4a(CB) (SEQ ID NO. 85) for CNBr cleavage, BspLU11 I site including Met codon was added at the 3′ end.

5) purF derivative F5 (SEQ ID NO. 87)

This derivative composed of a sequence from the 60^(th) methionine to the 148^(th) aspartic acid of the purF protein, and Ssp I site was added at the 3′ end.

6) purF derivative BF (SEQ ID NO. 89)

BF is a purF derivative of B. subtilis and includes 43 amino acid residues and Ssp I site coding for Asn at the 3′ end.

EXAMPLE 3 Preparation of DNA Construct Coding for Fused Peptides

Among the peptide genes prepared in Example 1, the genes encoding peptide that contains glycine at the first amino acid were fused to fusion partners for the hydroxylamine cleavage, F4a(HA), F5 and BF. Other peptides (HNP-I, Indolicidin, Tachyplesin) were fused to the fusion partners for the CNBr cleavage, F, F3(CB) and F4a(CB) (Table 3).

A method of fusion between the fusion partner and the gene coding for an antimicrobial peptide while producing the CNBr cleavage site (Met) or hydroxylamine cleavage site (Asn-Gly) is shown in FIGS. 3 and 4, respectively. In the case of fusion with fusion partner F for CNBr cleavage, the fusion partner and the MSI-344 gene were fused using the Nde I site to produce DNA construct FM (FIG. 3a). In case of fusion with F3(CB) or F4(CB), the peptide genes are chemically synthesized and fused to 3′ end BspLU11 I site of the fusion partner by complementary 5′ Nco I site for HNP-I, and 5′ BspLu11 I site for indolicidin and tachyplesin, respectively.

The fusion with the fusion partner for hydroxylamine cleavage (F′, F3(HA), F4(HA), F4a(HA), F5, BF) was carried out by cleaving the fusion partner with Ssp I and MSI-344 by Sma I, and connecting these DNA fragments to generate Asn-Gly site for the hydroxylamine cleavage. In the case of the genes for Apidaecin I, Bombinin, CPF1, Drosocin, Melittin, PGQ and XPF, it was not necessary to digest with restriction enzyme before the fusion with the fusion partner cleaved with Ssp I, since they have 5′ blunt ends.

EXAMPLE 4 Preparation of Transcriptionally Fused Multimer

A monomeric unit that can produce multimers was constructed consisting of Nde I site coding for Met, structural gene, RBS (SEQ ID NO. 91), and Ase I site that connects with Nde I to generate Met. As structural genes, F4a(HA)-MS 1344 fusion gene ( F4Ma ) and F5-MSI344 fusion gene ( F5M ) were used. The monomeric units were digested with Nde I and Ase I, and the isolated monomeric units were reconnected. Obtained DNA fragments were digested again with Nde I and Ase I, and the multimers were separated by agarose gel electrophoreses. By using this method, monomer (F4Ma), dimer (F4MaX2) and tetramer (F4MaX4) of F4Ma and monomer (F5M), dimer (Fm5MX2) and tetramer (F5MX4) of F5M were obtained.

EXAMPLE 5 Expression Vector

To express foreign gene in E. coli, two expression vectors pGNX2 and pT7K2.1 were constructed by using T7Φ10 promoter, high copy number replication origin (colEI of pUC family), and kanamycin resistance gene. To construct pGNX2, bla gene in commercially available pUC19 (ampicillin resistance gene: Amp^(R)) was substituted with kanamycin resistance gene (Kan^(R)). To this end, pUC19 was digested with Ssp I and Dra I to separate 1748 bp DNA fragment having 1748 bp, and Kan^(R) gene was amplified by PCR by using Tn5 of E. coli as a template and primers #39 and #40 (Table 1). The PCR product was digested with BamH I and Hind III, filled-in by Klenow treatment, and cloned int pUC19 digested with Ssp I and Dra I, resulting in pUCK2. After this vector was digested with Nde I and filled in by Klenow treatment, it was religated to contruct pUCK2ΔNdeI. The final plasmid pGNX2 was constructed by cloning the fragment containing T7Φ10 promoter and RBS from pT7-7 (USB, USA) that was digested with BamH I, filled-in by Klenow treatment, and then digested with Ase I, into the pUCK2ΔNdeI vector that was digested with Hind III, filld-in by Klenow treatment, and then digested with Ase I. T7Φ10 promoter and kanamycin resistant gene (Kan^(R)) are oriented to the same direction in pGNX2 (FIG. 6).

To construct the plasmid pT7K2.1, the bla gene was removed from pT7-7 by digestion with SspI and Bgl I, and the following treatment with T4 DNA polymerase to make blunt ends. Kan^(R) gene was prepared as in pGNX2 and the two DNA fragments were ligated to construct pT7K2. Final plasmid pT7K2.1 was constructed by removing Ase I site from this vector (FIG. 7). E. coli HMS174 (DE3) transformed with pGNX2 was deposited to Korean Collection of Type Cultures (KCTC) in Korea Research Institute of Bioscience and Biotechnology located at Yusong-gu Eun-dong, Taejon, Korea on May 29, 1998 and the number KCTC0486BP was given. To construct pGNX3, pGNX2F4M was partially digested with BspH I, and the fragment that has a cut in a single BspH I site was separated and further digested with BamH I. To prepare fragment containing T7 and rrnBT1T2 terminators, 132 bp fragment from pET11 a digested with BamH I and EcoR V and a 488 bp fragment from ptrc99a digested with BamH I and EcoR V were ligated. These fused fragments were cleaved by BamH I and BspH I, and cloned into the vector prepared as above to construct pGNX3F4M (FIG. 8).

To prepare pGNX4, a 3052 bp fragment was isolated from pETACc digested with Xba I and AlwN I, and a 2405 bp vector fragment from the pGNX3F4M digested with Xba I and AlwN I resulting in pGNX4F4M (FIG. 9).

To construct pGNX5, pGNX3F4M was partially digested with Ase I, then digested with Xba I, and treated with Klenow fragment. A fragment obtained from PCR-TrpPO digested with EcoR I and Nde I and then treated with Klenow fragment was cloned with the above vector fragment to construct pGNX5F4M (FIG. 10).

EXAMPLE 6 Production of Antimicrobial Peptides

DNA constructs obtained by fusing the MSI-344 to fusion partners, F3, F4, F4a, F5 and BF, were cloned into pGNX2 digested with Nde I and BamH I and pT7K2.1 digested with Nde I and BamH I, respectively. In case F (entire purF) was used as the fusion partner, it was cloned into pET24a (Novagen, USA) digested with Nde I and Xho I. In case of a multimer, it was cloned into the Nde I site of pGNX2 and pT7K2.1. The genes coding for Apidaecin I, Indolicidin, Tachyplesin I, Bombinin, CPF1, Drosocin, Melittin, HNP-I, PGQ and XPF were fused to the fusion partner F4 and cloned into pGNX2 digested with Nde I and EcoRI. When F3 was used, BamH I and EcoR I sites of pRSETc were used for cloning (Table 3).

The plasmids 2,3,4,5,6 and 7 in Table 3 were transformed into E.coli HMS174(DE3) by using the CaCl₂ method. R medium supplemented with casamino acid was used as a culture medium, and the peptide expression was induced when OD₆₀₀ was between 0.2 and 0.4 by adding 2% lactose and 2 mM IPTG, respectively. The expression level was quantified by scanning the results from SDS-PAGE by a densitometer and as the percent of fusion peptide in total cell proteins (FIG. 11). In FIG. 11, M represents molecular weight standard marker, and lanes 1 through 6 represent the expression from the transformants with plasmids 2,3,4,5,6, and 7 in Table 3 by lactose induction, and lanes 7 through 12 represent the expression from the transformants with plasmids 2,3,4,5,6, and 7 in Table 3 by IPTG induction. Lanes 13 and 14 represent the expression from the transformant with plasmid 43 (E. coli purF; EF) by lactose and IPTG induction, respectively. As in the same manner, MSI-344 was expressed using E.coli HMS174(DE3) transformed with plasmids 44, 45 and 46 in Table 3 and by lactose induction (FIG. 12). It can be seen that the expression level is higher with the plasmid having transcriptional terminator. With the HMS174 (DE3) transformed with plasmid 4 in Table 3, the expression of fusion peptide was induced by lactose and cells were harvested 9 hours after induction. The cells were sonicated and precipitates were obtained by centrifugation. After dissolving the precipitates by placing for 2 hours at room temperature in solution containing 9 M urea, 20 mM potassium phosphate (pH 8.5), the sample was loaded onto SP-sepharose FF column (Pharmacia, Sweden), and the fusion peptide F4Ma was eluted using 0.3˜1.0 M NaCl. Purified F4Ma was reacted in 0.5˜2 M hydroxylamine and 0.4 M potassium carbonate (pH 7.5-9.5) buffer to cleave MSI-344 from the fusion partner. After desalting, the reaction mixture was loaded onto SP sepharose FF column (Pharmacia, Sweden) again to elute MSI-344 with 0.4˜1 M NaCl. Purified MSI-344 was identified by HPLC, MALDI-MS and amino acid sequencing.

EXAMPLE 7

Other plasmids in Table 3 were transformed into E. coli HMS1 74 (DE3) by CaCl₂ method. R medium supplemented with casamino acid was used as a culture medium, and the peptide expression was induced by adding 2% lactose when OD₆₀₀ was between 0.4 and 0.6. The expression level was quantified by scanning the results from SDS-PAGE by a densitometer and as the percent of fusion peptide in total cell proteins. The results of the expression of each antimicrobial peptide are shown in FIGS. 13a and 13b and Table 3. In FIG. 13a, lanes 1 through 6 represent the results from the transformants with plasmids 10,12,15,20,21 and 23 in Table 3. In FIG. 13b, lanes 1 through 9 represent the results from the transformants with plasmids 11,13,14,16,22,17,18,24 and 19 in Table 3. FIGS. 14a-14 d represent the expression results of plasmids 25-42 in Table 3. Buforin IIbx2 and Buforin IIx4 are dimer and tetramer of Buforin IIb, respectively, and constructed as described in Example 4. The corresponding plasmids, systems and expression results were indicated in parenthesis below:

FIG. 14a: 1(25)

FIG. 14b: 1(26), 2(31), 3(36)

FIG. 14c: 1(27), 3(32), 3(37), 4(28), 5(33), 6(38), 7(29), 8(34), 9(39), 10(30), 11(35), 12(40)

FIG. 14d: 1(41), 2(42), 3(43)

Fusion Cleaving Cloning Expression No peptide partner method vector Plasmid strain rate (%) 1 MSI-344 F CNBr pET24a PETFM BL21(DE3) 9 (SEQ ID NO. 55) BLR(DE3) 2 MSI-344 F3 HA pGNX2 pGNX2F3M BL21(DE3) 10 (SEQ ID NO. 57) HMS174(DE3) 3 MSI-344 F4(HA) HA pGNX2 pGNX2F4M BL21(DE3) 30 (SEQ ID NO. 57) HMS174(DE3) JM109(DE3) UT400(DE3) UT5600(DE3) 4 MSI-344 F4(HA) HA pGNX2 pGNX2F4Ma BL21(DE3) 30 (SEQ ID NO. 57) HMS174(DE3) JM109(DE3) UT400(DE3) UT5600(DE3) 5 MSI-344 F4(HA) HA pT7K2.1 pT&KF4M BL21(DE3) 30 (SEQ ID NO. 57) HMS174(DE3) JM109(DE3) UT400(DE3) UT5600(DE3) 6 MSI-344 F4(HA) HA pT7K2.1 pT&KF4Ma BL21(DE3) 30 (SEQ ID NO. 57) a HMS174(DE3) JM109(DE3) UT400(DE3) UT5600(DE3) 7 MSI-344 F5 HA pGNX2 pGNX2F5M BL21(DE3) 20 (SEQ ID NO. 57) HMS174(DE3) 8 MSI-344 F5 HA pT7K2.1 pT7KF5M BL21(DE3) 20 (SEQ ID NO. 57) HMS174(DE3) 9 MSI-344 BF HA pGNX2 pGNX2BFM BL21(DE3) 12 (SEQ ID NO. 57) HMS174(DE3) 10 Apidaecin I F3 HA pRSETc pRF2Ap BL21(DE3) 25 (SEQ ID NO. 41) pLysS 11 Apidaecin I F4(HA) HA pGNX2 pGNX2F4Ap BL21(DE3) 8.7 (SEQ ID NO. 41) pLysS 12 Bombinin F3 HA pRSETc pRF3Bp BL21(DE3) 23 (SEQ ID NO. 43) pLysS 13 Bombinin F4(HA) HA pGNX2 pGNX2F4Ap BL21(DE3) 33.6 (SEQ ID NO. 43) pLysS 14 CPF F4(HA) HA pGNX2 pGNX2F4Cpf BL21(DE3) 9.0 (SEQ ID NO. 45) pLysS 15 Drosocin F3 HA pRSETC pRF3Dp BL21(DE3) 14 (SEQ ID NO. 47) pLysS 16 Drosocin F4(HA) HA pGNX2 pGNX2F4Dp BL21(DE3) 25 (SEQ ID NO. 47) pLysS 17 Melittin F4(HA) HA pGNX2 pGNX2F4Me1 BL21(DE3) 26 (SEQ ID NO. 53) pLysS 18 PGQ F4(HA) HA pGNX2 pGNX2F4Pg BL21(DE3) 20.2 (SEQ ID NO. 59) pLysS 19 XPF F4(HA) HA pGNX2 pGNX2F4Xp BL21(DE3) 26.5 (SEQ ID NO. 63) pLysS 20 HNP-I F3 CNBr pRSETc pRF3Hp BL21(DE3) 26.3 (SEQ ID NO. 49) pLysS 21 Indolicidin F3 CNBr pRSETc pRF3Id B21(DE3) 29 (SEQ ID NO. 51) pLysS 22 Indolicidin F4(CB) CNBr pGNX2 pGNX2F4Id BL21(DE3) 20.7 (SEQ ID NO. 51) pLysS 23 Tachyplesin I F3 CNBr pRSETc pRF3Tp BL21(DE3) 30 (SEQ ID NO. 61) pLysS 24 Tachyplesin I F4(CB) CNBr pGNX2 pGNX2F4Tp BL21(DE3) 21.8 (SEQ ID NO. 61) pLysS 25 Buforin I F4(HA) HA pGNX3 pGNX3F4BI HMS174(DE3) 25 (SEQ ID NO. 65) 26 Buforin II F4(HA) HA pGNX3 pGNX3F4BII HMS174(DE3) 30 (SEQ ID NO. 67) 27 Buforin II F5(HA) HA pGNX3 pGNX3F4BII HMS174(DE3) 20 (SEQ ID NO. 67) 28 Buforin II F5(HA) HA pGNX4 pGNX3F4BII HMS174(DE3) 18 (SEQ ID NO. 67) 29 Buforin II BF(HA) HA pGNX3 pGNX3F4BII HMS174(DE3) 4 (SEQ ID NO. 67) 30 Buforin II BF(HA) HA pGNX4 pGNX3F4BII HMS174(DE3) 4 (SEQ ID NO. 67) 31 Buforin IIa F4(HA) HA pGNX3 pGNX3F4BIIa HMS174(DE3) 28 (SEQ ID NO. 69) 32 Buforin IIa F5(HA) HA pGNX3 pGNX3F4BIIa HMS174(DE3) 20 (SEQ ID NO. 69) 33 Buforin IIa F5(HA) HA pGNX4 pGNX3F4BIIa HMS174(DE3) 18 (SEQ ID NO. 69) 34 Buforin IIa BF(HA) HA pGNX3 pGNX3F4BIIa HMS174(DE3) 4 (SEQ ID NO. 69) 35 Buforin IIa BF(HA) HA pGNX4 pGNX3F4BIIa HMS174(DE3) 4 (SEQ ID NO. 69) 36 Buforin IIb F4(HA) HA pGNX3 pGNX3F4BIIb HMS174(DE3) 25 (SEQ iD NO. 71) 37 Buforin IIb F5(HA) HA pGNX3 pGNX3F4BIIb HMS174(DE3) 20 (SEQ ID NO. 71) 38 Buforin IIb F5(HA) HA pGNX4 pGNX3F4BIIb HMS174(DE3) 18 (SEQ ID NO. 71) 39 Buforin IIb BF(HA) HA pGNX3 pGNX3F4BIIb HMS174(DE3) 20 (SEQ ID NO. 71) 40 Buforin IIb BF(HA) HA pGNX4 pGNX3F4BIIb HMS174(DE3) 15 (SEQ ID NO. 71) 41 Buforin IIbx2 BF(HA) HA pGNX4 pGNX3F4BIIbx2 HMS174(DE3) 20 (SEQ ID NO. 71) 42 Buforin IIbx4 BF(HA) HA pGNX4 pGNX3F4BIIbx4 HMS174(DE3) 20 (SEQ ID NO. 57) 43 MSI-344 EF HA pGNX2 pGNX2EFM HMS174(DE3) 30 (SEQ ID NO.57) 44 MSI-344 F4(HA) HA pGNX3 pGNX3F4M HMS174(DE3) 35 (SEQ ID NO. 57) 45 MSI-344 F4(HA) HA pGNX4 pGNX4F4M HMS174(DE3) 35 (SEQ ID NO. 57) 46 MSI-344 F4(HA) HA pGNX5 pGNX5F4M HMS174(DE3) 15 (SEQ ID NO. 57)

EXAMPLE 8

The constructs prepared in Example 4, such as monomer (F4Ma), dimer (F4MaX2) and tetramer (F4MaX4) of F4Ma and monomer (F5M), dimer (Fm5MX2) and tetramer (F5MX4) of F5M were transformed into E. coli HMS174 (DE3) after cloning them into Nde I site of pGNX2 and at Nde I site of pT7K2.1. Fusion protein was expressed following the method in Example 6, and the expression level was quantified by scanning the results from SDS-PAGE by a densitometer and as the percent of fusion peptide in total cell proteins. In FIG. 15, lanes 1-6 in pT7K2.1 represent F4Ma, F4MaX2, F4MaX4, F5M, F5MX2, and F5MX4, respectively. Lanes 1-4 in pGNX2 represent F4Ma, F4MaX2, F5M and F5MX2, respectively. As can be seen from FIG. 15, the expression level increased from 30% to 40% when the expression of tetramer was compared with that of the monomer. In the case of F5M, the expression level increased from 20% to 25% when the expression of tetramer was compared with that of monomer.

According to the present invention, antimicrobial peptides can be efficiently mass-produced from microorganisms more economically and can be separated and purified easily.

93 1 32 DNA Artificial Sequence primer for the synthesis of MSI-344 (32mer) 1 tccggatcca tatgggtatc ggcaaattcc tg 32 2 42 DNA Artificial Sequence primer for the synthesis of MSI-344 (42mer) 2 gcattaatat atctccttca ttactttttc aggattttaa cg 42 3 32 DNA Artificial Sequence primer for the synthesis of MSI-344 (32mer) 3 ggatcccggg atcggcaaat tcctgaaaaa gg 32 4 28 DNA Artificial Sequence primer for the synthesis of MSI-344 (28mer) 4 ggatccatta atatatctcc ttcattac 28 5 57 DNA Artificial Sequence primer for the synthesis of Apidaecin (57mer) 5 ggtaacaacc gtccggttta catcccgcag ccgcgtccgc cgcacccgcg tacttga 57 6 62 DNA Artificial Sequence primer for the synthesis of Apidaecin (62mer) 6 aattctcaag tacgcgggtg cggcggacgc ggctgcggga tgtaaaccgg acggttgtta 60 cc 62 7 48 DNA Artificial Sequence primer for the synthesis of Bombinin (48mer) 7 ggtatcggtg cgctgtctgc gaaaggtgcg ctgaaaggtc tggcgaaa 48 8 58 DNA Artificial Sequence primer for the synthesis of Bombinin (58 mer) 8 cgaattctca gttcgcgaag tgttgcgcca gacctttcgc cagacctttc agcgcacc 58 9 48 DNA Artificial Sequence primer for the synthesis of CPF (48mer) 9 ggtttcgcgt ctttcctggg taaagcgctg aaagcggcgc tgaaaatc 48 10 60 DNA Artificial Sequence primer for the synthesis of CPF (60mer) 10 cgaattctca ctgctgcggc gcaccaccca gcgcgttcgc accgattttc agcgccgctt 60 60 11 39 DNA Artificial Sequence primer for the synthesis of Drosocin (39mer) 11 ggtaaaccgc gtccgtactc tccgcgtccg acctctcac 39 12 49 DNA Artificial Sequence primer for the synthesis of Drosocin (49mer) 12 cgaattctca aaccgcgatc ggacgcgggt gagaggtcgg acgcggaga 49 13 60 DNA Artificial Sequence primer for the synthesis of HNP-1 (60mer) 13 gcatgccatg gcgtgctact gccgtatccc ggcgtgcatc gcgggtgaac gtcgttacgg 60 60 14 60 DNA Artificial Sequence primer for the synthesis of HNP-1 (60mer) 14 cgaattctca gcagcagaac gcccacagac gaccctggta gatgcaggta ccgtaacgac 60 60 15 47 DNA Artificial Sequence primer for the synthesis of Indolicidin (47mer) 15 catgatcctg ccgtggaaat ggccgtggtg gccgtggcgt cgttgag 47 16 47 DNA Artificial Sequence primer for the synthesis of Indolicidin (47mer) 16 aattctcaac gacgccacgg ccaccacggc catttccacg gcaggat 47 17 48 DNA Artificial Sequence primer for the synthesis of Melittin (48mer) 17 ggtatcggtg cggttctgaa agttctgacc accggtctgc cggcgctg 48 18 58 DNA Artificial Sequence primer for the synthesis of Melittin (58mer) 18 cgaattctca ctgctgacgt ttacgtttga tccaagagat cagcgccggc agaccggt 58 19 45 DNA Artificial Sequence primer for the synthesis of PGQ (45mer) 19 ggtgttctgt ctaacgttat cggttacctg aaaaaactgg gtacc 45 20 55 DNA Artificial Sequence primer for the synthesis of PGQ (55mer) 20 cgaattctca ctgtttcaga accgcgttca gcgcaccggt acccagtttt ttcag 55 21 59 DNA Artificial Sequence primer for the synthesis of Tachyplasin (59mer) 21 catgaaatgg tgcttccgtg tttgctaccg tggtatctgc taccgtcgtt gccgttgag 59 22 59 DNA Artificial Sequence primer for the synthesis of Tachyplasin (59mer) 22 aattctcaac ggcaacgacg gtagcagata ccccggtagc aaacacggaa gcaccattt 59 23 48 DNA Artificial Sequence primer for the synthesis of XPF (48mer) 23 ggttgggcgt ctaaaatcgg tcagaccctg ggtaaaatcg cgaaagtt 48 24 58 DNA Artificial Sequence primer for the synthesis of XPF (58mer) 24 cgaattctca tttcggctgg atcagttctt tcagaccaac tttcgcgatt ttacccag 58 25 30 DNA Artificial Sequence primer for the synthesis of F (30mer) 25 ggatccatat gtgcggtatt gtcggtatcg 30 26 25 DNA Artificial Sequence primer for the synthesis of F (25mer) 26 catatggcga gcttcaaata catcg 25 27 30 DNA Artificial Sequence primer for the synthesis of F′ (30mer) 27 ggatccatat gtgcggtatt gtcggtatcg 30 28 31 DNA Artificial Sequence primer for the synthesis of F′ (31mer) 28 ggatccaata ttagcttcaa atacatcgct c 31 29 30 DNA Artificial Sequence primer for the synthesis of F3 (30mer) 29 ggatccatat gtgcggtatt gtcggtatcg 30 30 37 DNA Artificial Sequence primer for the synthesis of F3(HA) (37mer) 30 ggatccaata ttcgcatgcg cagcttcaaa tacatcg 37 31 30 DNA Artificial Sequence primer for the synthesis of F3(CB) (30mer) 31 cgggatccac atgtggcgag cttcaaatac 30 32 30 DNA Artificial Sequence primer for the synthesis of F4 (30mer) 32 ggatccatat gtgcggtatt gtcggtatcg 30 33 24 DNA Artificial Sequence primer for the synthesis of F4(CB) (24mer) 33 gcggatccac atgtcggctt ccag 24 34 25 DNA Artificial Sequence primer for the synthesis of F3(HA) (25mer) 34 aatattgtcg gcttccagcg ggtag 25 35 23 DNA Artificial Sequence primer for the synthesis of BF (23mer) 35 catatgcttg ctgaaatcaa agg 23 36 30 DNA Artificial Sequence primer for the synthesis of BF (30mer) 36 aatattgcca gcaccctcct gtcctcggtg 30 37 18 DNA Artificial Sequence primer for purF G49A mutant (18mer) 37 ttcgcttgcg cgaccact 18 38 26 DNA Artificial Sequence primer for purF N102L mutant (26mer) 38 tgcgaacggg tggagccgtt agactg 26 39 34 DNA Artificial Sequence Primers for the synthesis of kanR gene (34mer) 39 gcggatccaa gagacaggat gaggatcgtt tcgc 34 40 40 DNA Artificial Sequence primer for the synthesis of kanR gene (40mer) 40 cggatatcaa gcttggaaat gttgaatact catactcttc 40 41 64 DNA Artificial Sequence APIDAECIN I gene 41 ggtaacaacc gtccggttta catcccgcag ccgcgtccgc cgcacccgcg tatctgagaa 60 ttcg 64 42 18 PRT Artificial Sequence APIDAECIN I peptide 42 Gly Asn Asn Arg Pro Val Tyr Ile Pro Gln Pro Arg Pro Pro His Pro 1 5 10 15 Arg Ile 43 82 DNA Artificial Sequence BOMBININ gene 43 ggtatcggtg cgctgtctgc gaaaggtgcg ctgaaaggtc tggcgaaagg tctggcggaa 60 cacttcgcga actgagaatt cg 82 44 24 PRT Artificial Sequence BOMBININE peptide 44 Gly Ile Gly Ala Leu Ser Ala Lys Gly Ala Leu Lys Gly Leu Ala Lys 1 5 10 15 Gly Leu Ala Glu His Phe Ala Asn 20 45 100 DNA Artificial Sequence CPFI gene 45 ggtttcgcgt ctttcctggg taaagcgctg aaagcgctga aagcggcgct gaaaatcggt 60 gcgaacgcgc tgggtggtgc gccgcagcag tgagaattcg 100 46 30 PRT Artificial Sequence CPFI peptide 46 Gly Phe Ala Ser Phe Leu Gly Lys Ala Leu Lys Ala Leu Lys Ala Ala 1 5 10 15 Leu Lys Ile Gly Ala Asn Ala Leu Gly Gly Ala Pro Gln Gln 20 25 30 47 67 DNA Artificial Sequence DROSOCIN gene 47 ggtaaaccgc gtccgtactc tccgcgtccg acctctcacc cgcgtccgat cgcggtttga 60 gaattcg 67 48 19 PRT Artificial Sequence DROSOCIN peptide 48 Gly Lys Pro Arg Pro Tyr Ser Pro Arg Pro Thr Ser His Pro Arg Pro 1 5 10 15 Ile Ala Val 49 110 DNA Artificial Sequence HNP-I gene 49 gcatgccatg gcgtgctact gccgtatccc ggcgtgcatc gcgggtgagc gtcgttacgg 60 tacctgcatc taccagggtc gtctgtgggc gttctgctgc tgagaattcg 110 50 30 PRT Artificial Sequence HNP-I peptide 50 Ala Cys Tyr Cys Arg Ile Pro Ala Cys Ile Ala Gly Glu Arg Arg Tyr 1 5 10 15 Gly Thr Cys Ile Tyr Gln Gly Arg Leu Trp Ala Phe Cys Cys 20 25 30 51 53 DNA Artificial Sequence INDOLICIDIN gene 51 catgatcctg ccgtggaaat ggccgtggtg gccgtggcgt cgttgagaat tcg 53 52 13 PRT Artificial Sequence INDOLICIDIN peptide 52 Ile Leu Pro Trp Lys Trp Pro Trp Trp Pro Trp Arg Arg 1 5 10 53 88 DNA Artificial Sequence MELITTIN gene 53 ggtatcggtg cggttctgaa agttctgacc accggtctgc cggcgctgat ctcttggatc 60 aaacgtaaac gtcagcagtg agaattcg 88 54 26 PRT Artificial Sequence MELLITIN peptide 54 Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu 1 5 10 15 Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln 20 25 55 103 DNA Artificial Sequence MSI-344(a) gene 55 tccggatcca tatgggtatc ggcaaattcc tgaaaaaggc taagaaattt ggtaaggcgt 60 tcgttaaaat cctgaaaaag taatgaagga gatatattaa tgc 103 56 23 PRT Artificial Sequence MSI-344(a) peptide 56 Met Gly Ile Gly Lys Phe Leu Lys Lys Ala Lys Lys Phe Gly Lys Ala 1 5 10 15 Phe Val Lys Ile Leu Lys Lys 20 57 100 DNA Artificial Sequence MSI-344(b) gene 57 ggatcccggg atcggcaaat tcctgaaaaa ggctaagaaa tttggtaagg cgttcgttaa 60 aatcctgaaa aagtaatgaa ggagatatat taatggatcc 100 58 22 PRT Artificial Sequence MSI-344(b) peptide 58 Gly Ile Gly Lys Phe Leu Lys Lys Ala Lys Lys Phe Gly Lys Ala Phe 1 5 10 15 Val Lys Ile Leu Lys Lys 20 59 88 DNA Artificial Sequence PGQ gene 59 ggtgttctgt ctaacgttat cggtatcggt tacctgaaaa aactgggtac cggtgcgctg 60 aacgcggttc tgaaacagtg agaattcg 88 60 26 PRT Artificial Sequence PGQ peptide 60 Gly Val Leu Ser Asn Val Ile Gly Ile Gly Tyr Leu Lys Lys Leu Gly 1 5 10 15 Thr Gly Ala Leu Asn Ala Val Leu Lys Gln 20 25 61 65 DNA Artificial Sequence TACHYPLASIN I gene 61 catgaaatgg tgcttccgtg tttgctaccg tggtatctgc taccgtcgtt gccgttgaga 60 attcg 65 62 17 PRT Artificial Sequence TACHYPLASIN I peptide 62 Lys Trp Cys Phe Arg Val Cys Tyr Arg Gly Ile Cys Tyr Arg Arg Cys 1 5 10 15 Arg 63 85 DNA Artificial Sequence XPF gene 63 ggttgggcgt ctaaaatcgg tcagaccctg ggtaaaatcg cgaaagttgg tctgaaagaa 60 ctgatccagc cgaaatgaga attcg 85 64 25 PRT Artificial Sequence XPF peptide 64 Gly Trp Ala Ser Lys Ile Gly Gln Thr Leu Gly Lys Ile Ala Lys Val 1 5 10 15 Gly Leu Lys Glu Leu Ile Gln Pro Lys 20 25 65 129 DNA Artificial Sequence BUFORIN I gene 65 ggcgcgggac gcggcaaaca aggaggcaaa gtgcgggcta aggccaagac ccgctcatcc 60 cgggcagggc tccagttccc ggtcggccgt gtgcacaggc tcctccgcaa gggcaactac 120 taaggatcc 129 66 40 PRT Artificial Sequence BUFORIN I peptide 66 Gly Ala Gly Arg Gly Lys Gln Gly Gly Lys Val Arg Ala Lys Ala Lys 1 5 10 15 Thr Arg Ser Ser Arg Ala Gly Leu Gln Phe Pro Val Gly Arg Val His 20 25 30 Arg Leu Leu Arg Lys Gly Asn Tyr 35 40 67 93 DNA Artificial Sequence BUFORIN II gene 67 gggacccgtt cctcccgtgc tggtctgcag ttcccggttg gtcgtgttca ccgtctgctg 60 cgtaaataat gaaggagata tattaatgga tcc 93 68 22 PRT Artificial Sequence BUFORIN II peptide 68 Gly Thr Arg Ser Ser Arg Ala Gly Leu Gln Phe Pro Val Gly Arg Val 1 5 10 15 His Arg Leu Leu Arg Lys 20 69 81 DNA Artificial Sequence BUFORIN IIa gene 69 gggcgtgctg gtctgcagtt cccggttggt cgtgttcacc gtctgctgcg taaataatga 60 aggagatata ttaatggatc c 81 70 18 PRT Artificial Sequence BUFORIN IIa peptide 70 Gly Arg Ala Gly Leu Gln Phe Pro Val Gly Arg Val His Arg Leu Leu 1 5 10 15 Arg Lys 71 93 DNA Artificial Sequence BUFORIN IIb gene 71 gggcgtgctg gtctgcagtt cccggttggt cgcctgctgc gccgtctgct gcgtcgcctg 60 ctgcgctaat gaaggagata tattaatgga tcc 93 72 22 PRT Artificial Sequence BUFORIN IIb peptide 72 Gly Arg Ala Gly Leu Gln Phe Pro Val Gly Arg Leu Leu Arg Arg Leu 1 5 10 15 Leu Arg Arg Leu Leu Arg 20 73 186 DNA Artificial Sequence F gene 73 catatgtgcg gtattgtcgg tatcgccggt gttatgccgg ttaaccagtc gatttatgat 60 gccttaacgg tgcttcagca tcgcggtcag gatgccgccg gcatcatcac catagatgcc 120 aataactgct tccgtttgcg taaagcgaac gggctggtga gcgatgtatt tgaagctcgc 180 catatg 186 74 61 PRT Artificial Sequence F peptide 74 Met Cys Gly Ile Val Gly Ile Ala Gly Val Met Pro Val Asn Gln Ser 1 5 10 15 Ile Tyr Asp Ala Leu Thr Val Leu Gln His Arg Gly Gln Asp Ala Ala 20 25 30 Gly Ile Ile Thr Ile Asp Ala Asn Asn Cys Phe Arg Leu Arg Lys Ala 35 40 45 Asn Gly Leu Val Ser Asp Val Phe Glu Ala Arg His Met 50 55 60 75 183 DNA Artificial Sequence F′ gene 75 catatgtgcg gtattgtcgg tatcgccggt gttatgccgg ttaaccagtc gatttatgat 60 gccttaacgg tgcttcagca tcgcggtcag gatgccgccg gcatcatcac catagatgcc 120 aataactgct tccgtttgcg taaagcgaac gcgctggtga gcgatgtatt tgaagctaat 180 att 183 76 59 PRT Artificial Sequence F′ peptide 76 Met Cys Gly Ile Val Gly Ile Ala Gly Val Met Pro Val Asn Gln Ser 1 5 10 15 Ile Tyr Asp Ala Leu Thr Val Leu Gln His Arg Gly Gln Asp Ala Ala 20 25 30 Gly Ile Ile Thr Ile Asp Ala Asn Asn Cys Phe Arg Leu Arg Lys Ala 35 40 45 Asn Ala Leu Val Ser Asp Val Phe Glu Ala Asn 50 55 77 192 DNA Artificial Sequence F3(HA) gene 77 catatgtgcg gtattgtcgg tatcgccggt gttatgccgg ttaaccagtc gatttatgat 60 gccttaacgg tgcttcagca tcgcggtcag gatgccgccg gcatcatcac catagatgcc 120 aataactgct tccgtttgcg taaagcgaac gcgctggtga gcgatgtatt tgaagctgcg 180 catgcgaata tt 192 78 62 PRT Artificial Sequence F3(HA) peptide 78 Met Cys Gly Ile Val Gly Ile Ala Gly Val Met Pro Val Asn Gln Ser 1 5 10 15 Ile Tyr Asp Ala Leu Thr Val Leu Gln His Arg Gly Gln Asp Ala Ala 20 25 30 Gly Ile Ile Thr Ile Asp Ala Asn Asn Cys Phe Arg Leu Arg Lys Ala 35 40 45 Asn Ala Leu Val Ser Asp Val Phe Glu Ala Ala His Ala Asn 50 55 60 79 145 DNA Artificial Sequence F3(CB) gene 79 catatgtgcg gtattgtcgg tatcgccggt gttatgccgg ttaaccagtc gatttatgat 60 gccttaacgg tgcttcagca tcgcggtcag gatgccgccg gcgctggtga gcgatgtatt 120 tgaagctcgc cacatgtgga tcccg 145 80 61 PRT Artificial Sequence F3(CB) peptide 80 Met Cys Gly Ile Val Gly Ile Ala Gly Val Met Pro Val Asn Gln Ser 1 5 10 15 Ile Tyr Asp Ala Leu Thr Val Leu Gln His Arg Gly Gln Asp Ala Ala 20 25 30 Gly Ile Ile Thr Ile Asp Ala Asn Asn Cys Phe Arg Leu Arg Lys Ala 35 40 45 Asn Ala Leu Val Ser Asp Val Phe Glu Ala Arg His Met 50 55 60 81 462 DNA Artificial Sequence F4(HA) gene 81 catatgtgcg gtattgtcgg tatcgccggt gttatgccgg ttaaccagtc gatttatgat 60 gccttaacgg tgcttcagca tcgcggtcag gatgccgccg gcatcatcac catagatgcc 120 aataactgct tccgtttgcg taaagcgaac gggctggtga gcgatgtatt tgaagctcgc 180 catatgcagc gtttgcaggg caatatgggc attggtcatg tgcgttaccc cacggctggc 240 agctccagcg cctctgaagc gcagccgttt tacgttaact ccccgtatgg cattacgctt 300 gcccacatcg gcaatctgac caacgctcac gagttgcgta aaaaactgtt tgaagaaaaa 360 cgccgccaca tcaacaccac ttccgactcg gaaattctgc ttaatatctt cgccagcgag 420 ctggacaact tccgccacta cccgctggaa gccgacaata tt 462 82 152 PRT Artificial Sequence F4(HA) peptide 82 Met Cys Gly Ile Val Gly Ile Ala Gly Val Met Pro Val Asn Gln Ser 1 5 10 15 Ile Tyr Asp Ala Leu Thr Val Leu Gln His Arg Gly Gln Asp Ala Ala 20 25 30 Gly Ile Ile Thr Ile Asp Ala Asn Asn Cys Phe Arg Leu Arg Lys Ala 35 40 45 Asn Gly Leu Val Ser Asp Val Phe Glu Ala Arg His Met Gln Arg Leu 50 55 60 Gln Gly Asn Met Gly Ile Gly His Val Arg Tyr Pro Thr Ala Gly Ser 65 70 75 80 Ser Ser Ala Ser Glu Ala Gln Pro Phe Tyr Val Asn Ser Pro Tyr Gly 85 90 95 Ile Thr Leu Ala His Ile Gly Asn Leu Thr Asn Ala His Glu Leu Arg 100 105 110 Lys Lys Leu Phe Glu Glu Lys Arg Arg His Ile Asn Thr Thr Ser Asp 115 120 125 Ser Glu Ile Leu Leu Asn Ile Phe Ala Ser Glu Leu Asp Asn Phe Arg 130 135 140 His Tyr Pro Leu Glu Ala Asp Asn 145 150 83 462 DNA Artificial Sequence F4a(HA) gene 83 catatgtgcg gtattgtcgg tatcgccggt gttatgccgg ttaaccagtc gatttatgat 60 gccttaacgg tgcttcagca tcgcggtcag gatgccgccg gcatcatcac catagatgcc 120 aataactgct tccgtttgcg taaagcgaac gcgctggtga gcgatgtatt tgaagctcgc 180 catatgcagc gtttgcaggg caatatgggc attggtcatg tgcgttaccc cacggctggc 240 agctccagcg cctctgaagc gcagccgttt tacgttaact ccccgtatgg cattacgctt 300 gcccacatcg gcaatctgac caacgctcac gagttgcgta aaaaactgtt tgaagaaaaa 360 cgccgccaca tcaacaccac ttccgactcg gaaattctgc ttaatatctt cgccagcgag 420 ctggacaact tccgccacta cccgctggaa gccgacaata tt 462 84 152 PRT Artificial Sequence F4a(HA) peptide 84 Met Cys Gly Ile Val Gly Ile Ala Gly Val Met Pro Val Asn Gln Ser 1 5 10 15 Ile Tyr Asp Ala Leu Thr Val Leu Gln His Arg Gly Gln Asp Ala Ala 20 25 30 Gly Ile Ile Thr Ile Asp Ala Asn Asn Cys Phe Arg Leu Arg Lys Ala 35 40 45 Asn Ala Leu Val Ser Asp Val Phe Glu Ala Arg His Met Gln Arg Leu 50 55 60 Gln Gly Asn Met Gly Ile Gly His Val Arg Tyr Pro Thr Ala Gly Ser 65 70 75 80 Ser Ser Ala Ser Glu Ala Gln Pro Phe Tyr Val Asn Ser Pro Tyr Gly 85 90 95 Ile Thr Leu Ala His Ile Gly Asn Leu Thr Asn Ala His Glu Leu Arg 100 105 110 Lys Lys Leu Phe Glu Glu Lys Arg Arg His Ile Asn Thr Thr Ser Asp 115 120 125 Ser Glu Ile Leu Leu Asn Ile Phe Ala Ser Glu Leu Asp Asn Phe Arg 130 135 140 His Tyr Pro Leu Glu Ala Asp Asn 145 150 85 462 DNA Artificial Sequence F4a(CB) gene 85 catatgtgcg gtattgtcgg tatcgccggt gttatgccgg ttaaccagtc gatttatgat 60 gccttaacgg tgcttcagca tcgcggtcag gatgccgccg gcatcatcac catagatgcc 120 aataactgct tccgtttgcg taaagcgaac gggctggtga gcgatgtatt tgaagctcgc 180 catatgcagc gtttgcaggg caatatgggc attggtcatg tgcgttaccc cacggctggc 240 agctccagcg cctctgaagc gcagccgttt tacgttaact ccccgtatgg cattacgctt 300 gcccacatcg gcaatctgac caacgctcac gagttgcgta aaaaactgtt tgaagaaaaa 360 cgccgccaca tcaacaccac ttccgactcg gaaattctgc ttaatatctt cgccagcgag 420 ctggacaact tccgccacta cccgctggaa gccgacatgt gg 462 86 152 PRT Artificial Sequence F5 gene 86 Met Cys Gly Ile Val Gly Ile Ala Gly Val Met Pro Val Asn Gln Ser 1 5 10 15 Ile Tyr Asp Ala Leu Thr Val Leu Gln His Arg Gly Gln Asp Ala Ala 20 25 30 Gly Ile Ile Thr Ile Asp Ala Asn Asn Cys Phe Arg Leu Arg Lys Ala 35 40 45 Asn Ala Leu Val Ser Asp Val Phe Glu Ala Arg His Met Gln Arg Leu 50 55 60 Gln Gly Asn Met Gly Ile Gly His Val Arg Tyr Pro Thr Ala Gly Ser 65 70 75 80 Ser Ser Ala Ser Glu Ala Gln Pro Phe Tyr Val Asn Ser Pro Tyr Gly 85 90 95 Ile Thr Leu Ala His Ile Gly Asn Leu Thr Asn Ala His Glu Leu Arg 100 105 110 Lys Lys Leu Phe Glu Glu Lys Arg Arg His Ile Asn Thr Thr Ser Asp 115 120 125 Ser Glu Ile Leu Leu Asn Ile Phe Ala Ser Glu Leu Asp Asn Phe Arg 130 135 140 His Tyr Pro Leu Glu Ala Asp Met 145 150 87 282 DNA Artificial Sequence F5 gene 87 catatgcagc gtttgcaggg caatatgggc attggtcatg tgcgttaccc cacggctggc 60 agctccagcg cctctgaagc gcagccgttt tacgttaact ccccgtatgg cattacgctt 120 gcccacatcg gcaatctgac caacgctcac gagttgcgta aaaaactgtt tgaagaaaaa 180 cgccgccaca tcaacaccac ttccgactcg gaaattctgc ttaatatctt cgccagcgag 240 ctggacaact tccgccacta cccgctggaa gccgacaata tt 282 88 92 PRT Artificial Sequence F5 peptide 88 Met Gln Arg Leu Gln Gly Asn Met Gly Ile Gly His Val Arg Tyr Pro 1 5 10 15 Thr Ala Gly Ser Ser Ser Ala Ser Glu Ala Gln Pro Phe Tyr Val Asn 20 25 30 Ser Pro Tyr Gly Ile Thr Leu Ala His Ile Gly Asn Leu Thr Asn Ala 35 40 45 His Glu Leu Arg Lys Lys Leu Phe Glu Glu Lys Arg Arg His Ile Asn 50 55 60 Thr Thr Ser Asp Ser Glu Ile Leu Leu Asn Ile Phe Ala Ser Glu Leu 65 70 75 80 Asp Asn Phe Arg His Tyr Pro Leu Glu Ala Asp Asn 85 90 89 138 DNA Artificial Sequence BF gene 89 catatgcttg ctgaaatcaa aggcttaaat gaagaatgcg gcgtttttgg gatttgggga 60 catgaagaag ccccgcaaat cacgtattac ggtctccaca gccttcagca ccgaggacag 120 gagggtgctg gcaatatt 138 90 44 PRT Artificial Sequence BF peptide 90 Met Leu Ala Glu Ile Lys Gly Leu Asn Glu Glu Cys Gly Val Phe Gly 1 5 10 15 Ile Trp Gly His Glu Glu Ala Pro Gln Ile Thr Tyr Tyr Gly Leu His 20 25 30 Ser Leu Gln His Arg Gly Gln Glu Gly Ala Gly Asn 35 40 91 15 DNA Artificial Sequence RBS binding site (15mer) 91 taatgaagga gatat 15 92 24 DNA Artificial Sequence Asel and RBS binding sites 92 aagtaatgaa ggagatatat taat 24 93 24 DNA Artificial Sequence Asel and RBS binding sites 93 ttcattacat cctctatata atta 24 

What is claimed is:
 1. A DNA construct comprising a first sequence encoding a peptide capable of neutralizing an antimicrobial activity of an antimicrobial peptide, said first sequence comprising a sequence selected from the group consisting of SEQ ID NOS: 73, 75, 77, 79, 81, 83, 85, 87 and 89 and encoding a purF peptide derived from a microorganism or a derivative of the purF peptide, and a second sequence encoding the antimicrobial peptide.
 2. A DNA construct according to claim 1 wherein the DNA construct is a multimeric DNA construct composed of repetitive units of 1) a first restriction enzyme site that can generate a methionine initiation codon and a first cohesive end, 2) a DNA construct, 3) a ribosome binding site (RBS), and 4) a second restriction enzyme site which can generate a second cohesive end which can be in-frame fused to the first cohesive end and thus generate the initiation codon.
 3. A method for producing an antimicrobial peptide which comprises; constructing an expression vector containing a genetic construct, said construct comprising a first sequence coding for a peptide capable of neutralizing an antimicrobial activity of an antimicrobial peptide, said first sequence comprising a sequence selected from the group consisting of SEQ ID NOS: 73, 75, 77, 79, 81, 83, 85, 87 and 89 and encoding a purF peptide derived from a microorganism or a derivative of the purF peptide, and a second sequence encoding the antimicrobial peptide; transforming bacterial host cells with said vector; culturing the transformed cell to express a peptide as a fusion protein; and recovering the fusion protein.
 4. A DNA construct according to claim 1, wherein the microorganism is selected from E. coli and B. subtilis.
 5. A DNA construct, comprising; a first sequence encoding a peptide capable of neutralizing an antimicrobial activity of an antimicrobial peptide, wherein the first sequence comprises a sequence encoding a peptide selected from the group consisting of SEQ ID NOS: 74, 76, 78, 80, 82, 84, 86, 88, and 90 and encodes a purF peptide derived from a microorganism or a derivative of the purF peptide, and a second sequence encoding the antimicrobial peptide.
 6. A DNA construct according to claim 1, wherein the antimicrobial peptide comprises a sequence selected from the group consisting of SEQ ID NOS: 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, and
 72. 7. A DNA construct according to claim 1, wherein the DNA construct comprises a third sequence between the first and second sequences, the third sequence encoding a cleavage site for a protease or a chemical.
 8. A DNA construct according to claim 7, wherein the protease is selected from Factor Xa and enterokinase, and the chemical is selected from CNBr and hydroxylamine. 